Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden

Journal of the American Society of Nephrology

Volumn 27, Issue 1, 2016, Pages 305-313

  Stubbs, Jason R ^a,b   House, John A ^c   Ocque, A Jacob ^d   Zhang, Shiqin ^a   Johnson, Cassandra ^a   Kimber, Cassandra ^b   Schmidt, Kyle ^a   Gupta, Aditi ^a,b   Wetmore, James B ^e   Nolin, Thomas D ^d,f   Spertus, John A ^a,g   Yu, Alan S ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^d Pharmaceutical Sciences Department   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f HENNEPIN COUNTY MEDICAL CENTER   (United States)

^g UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIMETHYLAMINE OXIDE; METHYLAMINE; TRIMETHYLOXAMINE;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; URINARY EXCRETION; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; KIDNEY TRANSPLANTATION; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC;

AGED; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; METHYLAMINES; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84954450626     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014111063     Document Type: Article

References (39)

1. US Renal Data System: USRDS 2013 Annual Report, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
3. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9[Suppl]: S16-S23, 1998
4. Jungers P, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie M, Lacour B, Descamps-Latscha B, Man NK: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrol Dial Transplant 12: 2597-2602, 1997
5. Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J: The risk of atherosclerosis in patients with chronic kidney disease. Int Urol Nephrol 45: 1605-1612, 2013
6. Menon V, Gul A, Sarnak MJ: Cardiovascular risk factors in chronic kidney disease. Kidney Int 68: 1413-1418, 2005
7. SarnakMJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, HammLL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, SpinosaDJ, Wilson PW; AmericanHeart AssociationCouncils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003
8. Koeth RA,Wang Z, Levison BS, Buffa JA,Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL: Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19: 576-585, 2013
9. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL: Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472: 57-63, 2011
10. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL: Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl JMed 368: 1575-1584, 2013
11. Wang Z, TangWH, Buffa JA, Fu X, Britt EB, Koeth RA, Levison BS, Fan Y, Wu Y, Hazen SL: Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J 35: 904-910, 2014
12. LangDH, YeungCK, Peter RM, IbarraC,Gasser R, Itagaki K, PhilpotRM, Rettie AE: Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: Selective catalysis by FMO3. Biochem Pharmacol 56: 1005-1012, 1998
13. Al-Waiz M, Mitchell SC, Idle JR, Smith RL: The metabolism of 14C-labelled trimethylamine and its N-oxide in man. Xenobiotica 17: 551-558, 1987
14. Mitchell SC, Zhang AQ, Noblet JM, Gillespie S, Jones N, Smith RL: Metabolic disposition of [14C]-trimethylamine N-oxide in rat: Variation with dose and route of administration. Xenobiotica 27: 1187-1197, 1997
15. Bain MA, Faull R, Fornasini G, Milne RW, Evans AM: Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. NephrolDial Transplant 21: 1300-1304, 2006
16. Rhee EP, Souza A, Farrell L, Pollak MR, Lewis GD, Steele DJ, Thadhani R, Clish CB, Greka A, Gerszten RE: Metabolite profiling identifies markers of uremia. J Am Soc Nephrol 21: 1041-1051, 2010
17. Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, Li XS, Levison BS, Hazen SL: Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 116: 448-455, 2015
18. Marso SP,Mehta SK, Frutkin A, House JA,McCrary JR, Kulkarni KR: Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in nondiabetic coronary arteries. Diabetes Care 31: 989-994, 2008
19. Lindsey JB, House JA, Kennedy KF, Marso SP: Diabetes duration is associated with increased thin-cap fibroatheroma detected by intravascular ultrasound with virtual histology. Circ Cardiovasc Interv 2: 543-548, 2009
20. Ramezani A, Raj DS: The gutmicrobiome, kidney disease, and targeted interventions. J Am Soc Nephrol 25: 657-670, 2014
21. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL: Chronic kidney disease alters intestinal microbial flora. Kidney Int 83: 308-315, 2013
22. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74: 349-355, 1996
23. Vaziri ND, Yuan J, Nazertehrani S, Ni Z, Liu S: Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol 38: 99-103, 2013
24. Magnusson M, Magnusson KE, Sundqvist T, Denneberg T: Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: Effects of low-and high-protein diets. Nephron 56: 306-311, 1990
25. Magnusson M, Magnusson KE, Sundqvist T, Denneberg T: Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 32: 754-759, 1991
26. de Almeida Duarte JB, de Aguilar-Nascimento JE, Nascimento M, Nochi RJ Jr: Bacterial translocation in experimental uremia. Urol Res 32: 266-270, 2004
27. Wolfe RA, Ashby VB,Milford EL,Ojo AO, Ettenger RE,Agodoa LY,Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl JMed 341: 1725-1730, 1999
28. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K: Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 270: 1339-1343, 1993
29. Chmielewski M, Bryl E, Marzec L, Aleksandrowicz E, Witkowski JM, Rutkowski B: Expression of scavenger receptor CD36 in chronic renal failure patients. Artif Organs 29: 608-614, 2005
30. Wu CC, Chen JS, Lin SH, Chu P, Lin YF, Lin SM, Liao TN: Aberrant activation of the TNF-alpha system and production of Fas and scavenger receptors on monocytes in patients with end-stage renal disease. Artif Organs 29: 701-707, 2005
31. Ando M, Lundkvist I, Bergström J, Lindholm B: Enhanced scavenger receptor expression in monocyte-macrophages in dialysis patients. Kidney Int 49: 773-780, 1996
32. Ando M, Gåfvels M, Bergström J, Lindholm B, Lundkvist I: Uremic serumenhances scavenger receptor expression and activity in the human monocytic cell line U937. Kidney Int 51: 785-792, 1997
33. Konishi Y, Okamura M, Konishi M, Negoro N, Yoshida T, Inoue T, Kanayama Y, Yoshikawa J: Enhanced gene expression of scavenger receptor in peripheral blood monocytes from patients on cuprophane haemodialysis. Nephrol Dial Transplant 12: 1167-1172, 1997
34. Zuo Y, Yancey P, Castro I, Khan WN, Motojima M, Ichikawa I, Fogo AB, Linton MF, Fazio S, Kon V: Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler Thromb Vasc Biol 29: 1277-1282, 2009
35. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
36. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63: 713-735, 2014
37. St. Luke's Mid America Heart Institute Imaging Core Laboratory website. http://www.saintlukeshealthsystem.org/imaging-core-lab-research-studies. Accessed September 2nd, 2014
38. Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51: 606, 1983
39. Ocque AJ, Stubbs JR, Nolin TD: Development and validation of a simple UHPLC-MS/MS method for the simultaneous determination of trimethylamine N-oxide, choline, and betaine in human plasma and urine. J Pharm Biomed Anal 109: 128-135, 2015